8-K: Ludwig Enterprises Unveils Promising Non-Invasive Breast Cancer Screening Technology at ASCO

Ludwig Enterprises announced the publication of an abstract at the ASCO 2025 Annual Meeting detailing a novel, non-invasive breast cancer scanning test utilizing mRNA from buccal cells and machine learning.

Summary

• Ludwig Enterprises (LUDG) announced the publication of an abstract on the American Society of Clinical Oncology (ASCO) website in connection with the ASCO 2025 Annual Meeting.
• The abstract details a novel, non-invasive scanning test for breast cancer, combining analysis of messenger RNA (mRNA) from non-invasively collected buccal (cheek) cells with machine learning algorithms.
• The study, titled "Non-invasively-collected buccal cell mRNA reveals novel breast cancer signal," highlights the potential of this approach to screen for breast cancer.
• Analysis identified a collection of six-biomarker combinations yielding excellent results with an F-score of 0.85.
• Two top-performing biomarker combinations were presented: System 1 (CASP9, ILIB, IL6, RGS2, SLC40A1, STK11) achieved Precision 0.892, Recall 0.913, F1 0.9, and AUC 0.897.
• System 2 (HAMP, ILIO, RGS2, SLC22A4, STK11, TGFB1) achieved Precision 0.888, Recall 0.902, F1 0.892, and AUC 0.849.
• The company, Ludwig Enterprises, Inc., is in the process of changing its name to Revealia Diagnostics, Inc.
• The company's mission is to identify, monitor, and create solutions to mitigate chronic inflammation, which is linked to illnesses like cancer and heart disease.

Sentiment

Score: 9

Explanation: The announcement details highly promising results for a novel, non-invasive breast cancer screening test, indicating significant scientific progress and potential for future clinical utility in a major disease area.

Positives

• Development of a novel, non-invasive breast cancer screening test using buccal cell mRNA and machine learning.
• The study identified biomarker combinations with excellent performance metrics, including an F-score of 0.85, and high precision, recall, F1, and AUC values.
• The non-invasive nature of the test (buccal swab) offers a significant advantage over more invasive diagnostic methods.
• The research addresses breast cancer, which is the most frequently diagnosed cancer globally, indicating a large potential market and significant medical need.
• The findings represent a potential step forward in developing less invasive screening options that could aid in the earlier detection of breast cancer.

Risks

• Actual results could differ materially from projected results due to certain risk factors.
• Potential risks and uncertainties include the company's ability to procure, appropriately price, retain, and complete projects.
• Risks also include changes in products and competition within the industry.
• Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc.

Future Outlook

The company's research demonstrates the potential for mRNA biomarker panels combined with machine learning to generate a signal for detecting breast cancer from non-invasively collected samples, suggesting clinical utility for early detection. Ludwig Enterprises aims to continue its mission to identify, monitor, and create solutions to mitigate chronic inflammation, which is a causative agent of major illnesses.

Management Comments

• "Ludwig Enterprises is pleased to now share these encouraging findings with the broader scientific community and the public, following the lifting of the ASCO embargo." Marvin S. Hausman, MD, Chief Science Officer at Ludwig Enterprises.
• "This research represents a potential step forward in developing less invasive screening options that could aid in the earlier detection of breast cancer." Marvin S. Hausman, MD, Chief Science Officer at Ludwig Enterprises.

Industry Context

Breast cancer remains the most frequently diagnosed cancer globally, highlighting a significant unmet medical need for improved screening methods. The use of mRNA analysis offers complementary diagnostic insights to traditional DNA genetic testing, particularly concerning inflammatory pathways linked to cancer development. The focus on non-invasive diagnostic tools aligns with broader industry trends towards patient-friendly and accessible healthcare solutions.

Stakeholder Impact

• Shareholders: Positive impact due to promising research results in a significant medical field, potentially leading to future commercialization and increased company value.
• Patients: Potential for a less invasive, more comfortable, and potentially earlier method for breast cancer detection.
• Scientific Community: Contribution of novel research findings and methodology to the field of oncology and diagnostics.

Next Steps

• Further development and potential clinical validation of the non-invasive breast cancer screening test based on these promising abstract findings.
• Continued research into mRNA genomics and machine learning AI to identify, monitor, and create solutions for mitigating chronic inflammation.

Key Dates

Recommendation

Keywords

Breast Cancer Screening, Non-invasive Diagnostics, mRNA Biomarkers, Machine Learning AI, Oncology, Early Detection, ASCO, Buccal Cells, Chronic Inflammation, Biotech, Healthcare